A Phase 2 interventional study of Fianlimab+cemiplimab in Melanoma, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing cemiplimab in Melanoma — 6 open to participants now, 9 under way, 1 of them phase 3. cemiplimab · Melanoma.
Among the 11 studies testing cemiplimab in Melanoma, this one is the 10th largest by enrollment, is one of 2 that started in 2025, is one of 8 in phase 2, and was the 8th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →6 of the 11 studies testing cemiplimab in Melanoma are open now, in 3 countries. Recruiting first, the newest first:
Grupo Español Multidisciplinar de Melanoma · Sites in Spain
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Canada
Ages 18+
University of California, Irvine · Sites in United States
By country, each count listing its studies:
cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 1
First in 2017; this study’s year is marked. 2 started in 2025.
This study's enrollment of 28 is below the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 87 across the 11 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 7 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
12 studies in Melanoma by Regeneron Pharmaceuticals: 2 open now, 6 under way, 3 of them phase 3. Of 5 finished, 2 (40%) have results posted.
Among the 12 studies in Melanoma by Regeneron Pharmaceuticals, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 2, and was the 12th registered.
Regeneron Pharmaceuticals’s Melanoma studies by the year they started, since 2016.
2 of the studies testing cemiplimab in Melanoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06246916Phase 3Regeneron PharmaceuticalsA Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | 2027-03-22 |
| NCT06594991Memorial Sloan Kettering Cancer CenterA Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing cemiplimab in Melanoma, from their registry updates:
Among Regeneron Pharmaceuticals’s 12 in Melanoma:
This tab as a report to print or save as PDF → With an account.
This study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated with fianlimab and cemiplimab in the study called R3767-ONC-1613 (NCT03005782).
The aim of the current study is to see how safe and effective the study drugs are in a long-term follow-up. No study drug will be given during this study. Cancer status will be monitored, in addition to routine care. The study is also collecting information about general health status, and other treatments that may have been received since participation in study R3767-ONC-1613 (NCT03005782).
Key Inclusion Criteria:
1. Participants with melanoma who enrolled in cohorts 6, 15, or 16 of study R3767-ONC- 1613 (NCT03005782)
Key Exclusion Criteria:
None
Note: Other protocol-defined Inclusion/ Exclusion criteria may apply
Drug: Fianlimab+cemiplimab
Drug: Fianlimab+cemiplimab
Drug pages: Fianlimab · Cemiplimab
No study drug administered in this observational study.
Also known as: REGN3767, REGN2810, Libtayo®
Death from any cause starting at time of initial treatment with fianlimab and cemiplimab in study R3767-ONC-1613
Time frame: Up to 4 years
Progressive-Free Survival (PFS)
Time frame: Up to 4 years
Objective Response Rate (ORR)
Time frame: Up to 4 years
Duration of Response (DOR)
Time frame: Up to 4 years
Disease Control Rate (DCR)
Time frame: Up to 4 years
Incidence of Serious Adverse Events (SAEs)
Time frame: Up to 4 years
Severity of SAEs
Time frame: Up to 4 years
Incidence of treatment-related AEs
Time frame: Up to 4 years
Severity of treatment-related AEs
Time frame: Up to 4 years
Incidence of anti-cancer therapies received since end of treatment with fianlimab and cemiplimab in study R3767-ONC-1613
Time frame: Up to 4 years
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Oct 2030, 65 months after the start.
Of 106 industry-sponsored phase 2 interventional studies under Melanoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 60. This study's planned 65 months is above that.
Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2029 → Oct 2030 and completion Oct 2029 → Oct 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fianlimab · Cemiplimab